How to resolve AdBlock issue? Ology Bioservices receives $8.4 Million award to produce Anti-Ebola medical countermeasure
Under terms of the contract, Ology Bioservices will perform technology transfer of the Ebola mAbs production process into the Department of Defense Advanced Development Manufacturing Facility (DoD ADM). The DoD ADM Facility is a 183,000-square foot, state-of-the-art, multi-purpose, multi-product, Biosafety Level 3-capable facility operated by the company in Alachua, Florida. The product will be produced using cGMP manufacturing at a volume of 500 L and is expected to be delivered in December 2018. The agreement includes an option for two additional manufacturing lots to be delivered in early 2019.
“Given the inherent danger posed by Ebola to the global population, there is an urgent need to mitigate future outbreaks by ensuring rapid and efficient manufacturing and delivery of a protective countermeasure. Based on our successful work with other important biologics countermeasures, we are pleased to have been selected by the DoD to provide this critical product,” stated Peter H. Khoury, Ph.D., MBA, President and Chief Executive Officer of Ology Bioservices.